EOFlow EOPatch (GlucoMen Day PUMP)

The EOFlow EOPatch — sold in Europe by Menarini as the GlucoMen Day PUMP — was, on paper, a genuine rival to Omnipod: a fully tubeless, disposable patch pump controlled entirely from a smartphone app called Narsha, with no separate handheld and no tubing. It was compact and light (26g empty), water-resistant, held a 200-unit reservoir of rapid-acting insulin, and was worn for about 3.5 days, making it the world's second commercialized disposable patch pump after Omnipod. Launched on a CE mark from 2021, it reached around 69,000 users across Europe, and a partnership with Diabeloop aimed to turn it into a wearable automated insulin delivery system using the DBLG1 algorithm. That future never arrived. Insulet pursued EOFlow on two fronts — trade secrets in the United States, patents in Europe — a $738M Medtronic acquisition collapsed, and in July 2025 the Unified Patent Court ordered the pump banned and recalled across 17 European countries for infringing an Insulet patent, with daily penalties for further sales.

The litigation has not gone all one way, and it is worth being precise about which case did what. The US case was about trade secrets: a Massachusetts jury awarded Insulet $452M in 2024, the district court cut that to roughly $59.4M, and on 28 May 2026 a divided panel of the Federal Circuit reversed the trade-secret judgment outright, holding that Insulet had waited too long — the claim was time-barred under the Defend Trade Secrets Act's three-year limit, because Insulet knew or should have known of the alleged misappropriation years before it sued in 2023. That was a real win for EOFlow, and it removed the US damages award and the US injunction. But it is a different case from the one that took the pump away from patients. The European action is a patent case, decided by the Unified Patent Court, and the American appeal does not touch it: the EU ban and recall across 17 countries still stand. We have found no evidence it has been lifted.

So the pump remains gone. It is included here as a notable, instructive case: a credible tubeless pump removed from the market by litigation, not by clinical failure, and effectively unavailable to patients today. If the European injunction were ever lifted or licensed around, this record would change — but that has not happened, and nothing in the US ruling makes it happen.